AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22133165 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care.
Number of subjects: 98
Study 19758253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice slurry containing 5,000 ppm F
Number of subjects: 28
Study 19758253 — intervention group
Group type: COMPARATOR
Intervention: Water solutions containing 1.5% SLS
Number of subjects: 28
Study 16766439 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of attitudes and beliefs about hypnosis among college students.
Number of subjects: 280
Study 15249273 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 21
Study 15249273 — intervention group
Group type: COMPARATOR
Intervention: Galantamine
Number of subjects: 21
Study 15249273 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine
Number of subjects: 21
Study 15249273 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 21
Study 15249273 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (high-dose)
Number of subjects: 21
Study 11549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 15
Study 11549648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9526696 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program
Number of subjects: 241
Study 30326124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (200 mg once or twice per day)
Number of subjects: 1578
Study 30326124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578
Study 27238068 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy for mothers (IPT-MOMS)
Number of subjects: 168
Study 27238068 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive psychotherapy (BSP)
Number of subjects: 168
Study 27238068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (IPT-MOMS and BSP)
Number of subjects: 168
Study 25622742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Ropivacaine (RD)
Number of subjects: 60
Study 25622742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl + Ropivacaine (RF)
Number of subjects: 60
Study 25622742 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline + Ropivacaine (RN)
Number of subjects: 60
Study 22831283 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial diversity at day 7 (measured by AluI)
Number of subjects: 98
Study 22831283 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial diversity at day 7 (measured by Sau96I)
Number of subjects: 98
Study 22831283 — intervention group
Group type: COMPARATOR
Intervention: Microbial diversity
Number of subjects: 98
Study 19476479 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 b.i.d.
Number of subjects: 600
Study 19476479 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 50 t.i.d.
Number of subjects: 600
Study 19476479 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 70 t.i.d.
Number of subjects: 600
Study 19476479 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 50 and BIAsp 30 b.i.d.
Number of subjects: 600
Study 16928705 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (10.7 cm H(2)O)
Number of subjects: 28
Study 16928705 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (4 cm H(2)O)
Number of subjects: 28
Study 15219522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1000 mg
Number of subjects: 432
Study 15219522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1500 mg
Number of subjects: 432
Study 15219522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 2000 mg
Number of subjects: 432
Study 15219522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 3000 mg
Number of subjects: 432
Study 11285986 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration with oocyte collection intervals of 33-41 hours
Number of subjects: 533
Study 11285986 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration
Number of subjects: 533
Study 9676345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 8
Study 9676345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9676345 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (500 mg b.i.d.)
Number of subjects: 8
Study 7929712 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-injured patients (HI)
Number of subjects: 40
Study 7929712 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 3209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) - 4 doses for 2 days
Number of subjects: 422
Study 3209607 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin combined with cloxacillin (BPC) - 6 doses for 3 days
Number of subjects: 422
Study 3209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with additional antibiotics for fever (CTX-ADD)
Number of subjects: 422
Study 3209607 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin combined with cloxacillin with additional antibiotics for fever (BPC-ADD)
Number of subjects: 422
Study 3209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) or CTX-ADD
Number of subjects: 422
Study 3209607 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin combined with cloxacillin (BPC) or BPC-ADD
Number of subjects: 422
Study 3209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 422
Study 30642737 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic plus selenium (200 μg/day selenium + 2 × 10^9 CFU/day of Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum)
Number of subjects: 79
Study 30642737 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic plus selenium
Number of subjects: 79
Study 30642737 — intervention group
Group type: COMPARATOR
Intervention: Selenium (200 μg/day)
Number of subjects: 79
Study 30642737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 28315596 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises for hip and trunk muscles (three weekly sessions for eight weeks)
Number of subjects: 34
Study 28315596 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control group)
Number of subjects: 34
Study 25562195 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba mate tea (5 g/day) for 6 weeks
Number of subjects: 142
Study 25562195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g/day) for 6 weeks
Number of subjects: 142
Study 23165981 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care from a movement disorders specialist, PD nurses, and social worker
Number of subjects: 122
Study 21999374 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cells (ASC) injection
Number of subjects: 20
Study 21999374 — intervention group
Group type: COMPARATOR
Intervention: Traditional compression sleeve therapy (CST)
Number of subjects: 20
Study 18181136 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups
Number of subjects: 10
Study 17130417 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from the clinical phase III US Insulin‐like Growth Factor‐I Trial
Number of subjects: 207
Study 17130417 — intervention group
Group type: EXPERIMENTAL
Intervention: Database group of ALS patients
Number of subjects: 207
Study 17130417 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from the clinical phase III trial
Number of subjects: 207
Study 17130417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox analysis for both groups
Number of subjects: 207
Study 15276488 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopy (group A; n = 46)
Number of subjects: 90
Study 15276488 — intervention group
Group type: COMPARATOR
Intervention: Axillary thoracotomy (group B; n = 44)
Number of subjects: 90
Study 11775033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vocational intervention consisting of sociomedical examination, multidisciplinary assessment, and individual sociomedical rehabilitation plans.
Number of subjects: 201
Study 11775033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vocational intervention
Number of subjects: 201
Study 11775033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study 9269013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated titanium plasma-sprayed implants
Number of subjects: 65
Study 9269013 — intervention group
Group type: COMPARATOR
Intervention: Titanium plasma-sprayed implants
Number of subjects: 65
Study 8305165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg x min nifedipine
Number of subjects: 8
Study 8305165 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mumol/min magnesium
Number of subjects: 8
Study 8305165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg x min nifedipine plus 100 mumol/min magnesium
Number of subjects: 8
Study 8305165 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 8
Study 3545647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion
Number of subjects: 22
Study 3545647 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (ANG II) infusion
Number of subjects: 22
Study 31311239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive Initiation Training (RIT)
Number of subjects: 20
Study 31311239 — intervention group
Group type: COMPARATOR
Intervention: Shuttle Run (SR)
Number of subjects: 20
Study 28055025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 25
Study 28055025 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallowing study (VFSS)
Number of subjects: 25
Study 26115159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 50
Study 26115159 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 24046411 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 nmol of c-di-GMP administered intramuscularly (IM) in conjunction with penicillin G for 5 days
Number of subjects: 0
Study 24046411 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with saline and penicillin G
Number of subjects: 0
Study 24046411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavage treatment with 20 nmol of c-di-GMP in conjunction with penicillin G
Number of subjects: 0
Study 24046411 — intervention group
Group type: EXPERIMENTAL
Intervention: IM treatment with c-di-GMP
Number of subjects: 0
Study 24046411 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 22141214 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during anesthetic induction
Number of subjects: 40
Study 22141214 — intervention group
Group type: COMPARATOR
Intervention: No parental presence during anesthetic induction
Number of subjects: 40
Study 19674132 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy plus bismuth subcitrate (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., bismuth subcitrate 300 mg q.i.d. for 14 days)
Number of subjects: 160
Study 19674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus bismuth subcitrate and vitamins C (500 mg b.i.d.) and E (200 IU b.i.d. for 30 days)
Number of subjects: 160
Study 19674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 17175645 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai injection (40 ml) with 250 ml 50 g/L glucose solution for 3 days, 1 time per day
Number of subjects: 20
Study 17175645 — intervention group
Group type: COMPARATOR
Intervention: Control group with 290 ml 50 g/L glucose injection liquid for 3 days, 1 time per day
Number of subjects: 20
Study 15608587 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute motivational/skills-building HIV risk reduction counseling intervention
Number of subjects: 228
Study 15608587 — intervention group
Group type: COMPARATOR
Intervention: 20-minute HIV information/education session
Number of subjects: 228
Study 11353932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (10 ng/kg/min for 1 hour)
Number of subjects: 10
Study 11353932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation (20 ppm for 1 hour)
Number of subjects: 10
Study 9398951 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 rocuronium + 1.5 mg.kg‐1 succinylcholine
Number of subjects: 75
Study 9398951 — intervention group
Group type: COMPARATOR
Intervention: Normal saline followed by 1.0 mg.kg‐1 succinylcholine
Number of subjects: 75
Study 8435812 — intervention group
Group type: COMPARATOR
Intervention: Accelerated hyperfractionated radiation therapy at 48 Gy
Number of subjects: 153
Study 8435812 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 54.4 Gy
Number of subjects: 153
Study 8435812 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 64 Gy
Number of subjects: 153
Study 8435812 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 70.4 Gy
Number of subjects: 153
Study 3599794 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse‐grained breads
Number of subjects: 103
Study 3599794 — intervention group
Group type: COMPARATOR
Intervention: Finer grained breads or breads produced from flour
Number of subjects: 103
Study 28107027 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based intervention targeting executive functions and parent-child relationships
Number of subjects: 68
Study 29056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit One device
Number of subjects: 36
Study 26553413 — intervention group
Group type: EXPERIMENTAL
Intervention: Endourethral collagen type 2 injection
Number of subjects: 24
Study 26553413 — intervention group
Group type: COMPARATOR
Intervention: Endourethral saline water injection
Number of subjects: 24
Study 23992605 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-40 mm Hg graduated compressive stockings (GCS)
Number of subjects: 69
Study 23992605 — intervention group
Group type: COMPARATOR
Intervention: No stockings
Number of subjects: 69
Study 22648218 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin 1% gel (BPO/C)
Number of subjects: 168
Study 22648218 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel (AP)
Number of subjects: 168
Study 19601709 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 300 microg subcutaneously Q3W
Number of subjects: 386
Study 19601709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 17525166 — intervention group
Group type: EXPERIMENTAL
Intervention: valdecoxib 20 mg bid
Number of subjects: 197
Study 17525166 — intervention group
Group type: EXPERIMENTAL
Intervention: valdecoxib 40 mg qd
Number of subjects: 197
Study 17525166 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 15302981 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 119
Study 15302981 — intervention group
Group type: EXPERIMENTAL
Intervention: eprosartan 600 mg
Number of subjects: 119
Study 15302981 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 119
Study 12049152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu (6 oz/day)
Number of subjects: 14
Study 12049152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu + Orange Juice (6 oz tofu + 303 mg vitamin C/day)
Number of subjects: 14
Study 12049152 — intervention group
Group type: COMPARATOR
Intervention: Control (T group)
Number of subjects: 14
Study 9834279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg twice daily for 2 weeks
Number of subjects: 60
Study 9834279 — intervention group
Group type: COMPARATOR
Intervention: Imipenem 500 mg three times daily for 2 weeks
Number of subjects: 60
Study 8115618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast agent
Number of subjects: 46
Study 8115618 — intervention group
Group type: COMPARATOR
Intervention: Nonionic contrast agent
Number of subjects: 46
Study 2552740 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms immune globulin anti-D administered prenatally
Number of subjects: 609
Study 2552740 — intervention group
Group type: COMPARATOR
Intervention: Control group (354 women who did not receive prenatal immune globulin)
Number of subjects: 609
Study 2552740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal prophylaxis group
Number of subjects: 609
Study 1255329 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (124 children)
Number of subjects: 246
Study 1255329 — intervention group
Group type: COMPARATOR
Intervention: Control group (122 children)
Number of subjects: 246
Study 31254681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at TE3 and TE5 for 30 minutes
Number of subjects: 54
Study 27931887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 20
Study 27931887 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 25263212 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg twice‐daily)
Number of subjects: 107
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (240 mg twice‐daily)
Number of subjects: 107
Study 23182627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (for MET-high tumours)
Number of subjects: 107
Study 23182627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for MET-high tumours)
Number of subjects: 107
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 107
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg
Number of subjects: 107
Study 23182627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 240 mg
Number of subjects: 107
Study 21817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intratympanic dexamethasone with systemic steroids
Number of subjects: 88
Study 21817157 — intervention group
Group type: COMPARATOR
Intervention: Subsequent intratympanic dexamethasone given 7 days after systemic treatment
Number of subjects: 88
Study 21817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent intratympanic dexamethasone
Number of subjects: 88
Study 21817157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone treatment
Number of subjects: 88
Study 19118304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg per day for 3 years
Number of subjects: 51
Study 19118304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (various doses)
Number of subjects: 51
Study 19118304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment discontinued for 1 year
Number of subjects: 51
Study 19118304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16836917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 41
Study 16836917 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 41
Study 15522047 — intervention group
Group type: EXPERIMENTAL
Intervention: CEqual program for quantifying size of perfusion defects
Number of subjects: 13
Study 15522047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedars‐Sinai quantitative gated single‐photon emission tomography program for quantifying left ventricular function
Number of subjects: 13
Study 11195997 — intervention group
Group type: EXPERIMENTAL
Intervention: PerMag participants
Number of subjects: 159
Study 11195997 — intervention group
Group type: EXPERIMENTAL
Intervention: SocAnh participants
Number of subjects: 159
Study 11195997 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 159
Study 9030681 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 oz of yogurt containing live, active Lactobacillus bulgaricus and Streptococcus thermophilus
Number of subjects: 20
Study 9030681 — intervention group
Group type: COMPARATOR
Intervention: 16 oz of milk (2% milk)
Number of subjects: 20
Study 8301102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (12 mg/kg)
Number of subjects: 10
Study 8301102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (30 mg/kg)
Number of subjects: 10
Study 4029186 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive index based on clinical variables available at discharge (history of hypertension, angina pectoris, diabetes, maximal serum ASAT during MI)
Number of subjects: 1306
Study 4029186 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive index including cessation of smoking after MI
Number of subjects: 1306
Study 4029186 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarctions occurring before the median follow‐up time of 21 months
Number of subjects: 1306
Study 31840832 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision ACL reconstruction
Number of subjects: 0
Study 29523409 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 522
Study 29523409 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 522
Study 26782346 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV plus dexamethasone (1mg/d)
Number of subjects: 72
Study 26782346 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1mg/d) alone
Number of subjects: 72
Study 24831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, orally)
Number of subjects: 285
Study 24831979 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2, intravenously, every 21 days, or docetaxel 75 mg/m2, intravenously, every 21 days)
Number of subjects: 285
Study 24831979 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 285
Study 24831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 285